U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483099) titled 'A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease' on March 16.
Brief Summary: The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Crohn Disease
Intervention:
DRUG: LY4395089
Administered orally
DRUG: Mirik...